Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
Completed · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer. The investigators will determine the tolerable dose of (oral) vinorelbine in combination with (oral) estramustine, and evaluate the efficacy of this treatment for patients with hormone-refractory prostate cancer.
Key facts
- Study ID
- NCT00151086
- Run by
- University of Michigan Rogel Cancer Center
- People needed
- 33
- Starts
- 2001-12-01
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2015-01-22
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.